The FDA today approved the first drug, known as Truvada, for preventing HIV in people at high risk of infection due to ‘discordance’ – science lingo for being HIV negative but having a sex partner who is HIV positive.
Seattle scientists played a critical role in demonstrating the drug’s effectiveness in Kenya and Uganda studies.
